• News
  • SAN DIEGO
  • BioTech

La Jolla Institute elects three execs to board

La Jolla Institute for Allergy and Immunology recently elected three San Diego business executives to its board of directors.

The new members are: Sergio Jinich, a real estate and construction executive in the United States and Mexico; Tina Nova, Ph.D., a scientist and co-founder of three San Diego biotechnology companies; and Timothy Wollaeger, a biotechnology industry veteran with experience in corporate finance, management and venture capital, who co-founded many San Diego biotechnology companies.

“We are honored to attract these high-caliber individuals to our board of directors,” said Mitchell Kronenberg, Ph.D., La Jolla Institute president and chief scientific officer. “Each brings a track record of extraordinary success, experience and leadership that is a perfect complement to our existing board of respected business and scientific leaders.”

Jinich is chairman of Paragon Management Company, a real estate investment firm. Previously, Jinich served for 24 years as chairman of Grupo COIN in Mexico, a construction and real estate firm. During this time, Jinich served as president of the Mexican Chamber of the Construction Industry and vice president for Concamin, the Confederation of Industrial Chambers of Commerce in Mexico.

Jinich has been involved with several community groups, including serving on the Executive Committee Policy Board for USD's Burnham-Moores Center for Real Estate, and as chairman of the American Israel Public Affairs Committee in San Diego.

Nova is co-founder of Genoptix Inc., a laboratory diagnostics company specializing in blood cancers. Nova served as Genoptix president and CEO for 14 years, from its founding in 2000 through March 2014. Nova also co-founded Nanogen Inc., a provider of molecular diagnostic tests, and was its COO and president from 1994 to 2000. She co-founded Selective Genetics in 1992, a biotech focused on eye diseases.

Nova serves on the board of Rady Children’s Hospital and was formerly on the board of the University of San Diego. She also served as chair of Biocom from 2001 to 2002. Nova also serves on the boards of Arena Pharmaceuticals (Nasdaq: ARNA) and Adamis Pharmaceuticals (Nasdaq: ADMP).

Wollaeger has more than 30 years of experience in the medical products and biotechnology fields in both corporate finance, management and venture capital and helped launch many major San Diego biotechnology companies.

Wollaeger joined Sanderling Ventures, one of the oldest biomedical investment firms, as a managing director in 2002 to open the firm's San Diego office. He serves on the board of directors for several Sanderling portfolio companies in San Diego, including CalciMedica, and Chimerix (now headquartered in North Carolina), and is chairman of the board of Sotera Wireless and Asteras.

Before joining Sanderling, Wollaeger founded and served as general partner of Kingsbury Capital Partners, a venture capital firm in San Diego. Wollaeger was named Ernst & Young San Diego’s Entrepreneur of the Year in 1995, Corporate Director of the Year in 2001, and was awarded a Lifetime Achievement Award from the San Diego Corporate Directors Forum in 2013.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

La Jolla Institute for Allergy and Immunology

Company Website

9420 Athena Cir.
La Jolla, CA 92037

La Jolla Institute for Allergy and Immunology Executive(s):

Mitchell Kronenberg, Ph.D.

  • Chief Scientific Officer, President

Other Lists

2015